Business Wire India

(5th September, 2014; Business Wire India); “India & Japan have a big opportunity of working together in the area of healthcare. Japan has achieved its goal of longevity and healthy life for all its citizens. This knowledge and technology will benefit India as well as the rest of the world. Shri Narendra Modi, Hon’ble Prime Minister of India, has already extended an open invitation to COME MAKE IN INDIA.  India will give Japan a huge consuming population, excellent human resources and a low cost base for manufacturing and exporting healthcare solutions to the world”, said Rajesh Srivastava, Chairman, Rockland Hospitals. He was speaking on the topic: Creating Healthcare Access for Cancer Treatment: Sharing Japanese Solutions, during a two days seminar titled FICCI- Heal-2014 on 1 & 2 Sept in Delhi.

(2nd September, 2014; Business Wire India); Five years on from the first breakthrough presentation of the pivotal RE-LY^® clinical trial of Pradaxa^® (dabigatran etexilate) for the prevention of stroke in non-valvular atrial fibrillation (NVAF), extensive clinical trial and real-world data support Pradaxa^® in various indications. Boehringer Ingelheim continues to grow the evidence base for Pradaxa^® to improve care for patients at risk of blood clots and today announces the initiation of Phase III of the GLORIA™-AF registry program in North America and in Europe. During this final phase of the registry program, data on the overall safety and effectiveness of antithrombotic treatments will be collected.

(5th August, 2014; Business Wire India); Studies since 2012 have estimated that over 74% of urban Indians are overweight (i.e. BMI over 23 kg/m²). A recent survey conducted by Fitho, a leading wellness services organization that works with partners like Lal Pathlabs, showed that along with increasing weight, there is also increasing awareness and 5 out of 10 urban Indians are trying to lose weight. While 40% of the overweight people have intent to lose weight but are not taking action to control their weight, the remaining 60% are making an effort to lose weight. The survey revealed that looking good, keeping fit and staying confident are the major reasons for the women and men under 35 to lose weight, while people aged over 35 and the heavily overweight (BMI>25 kg/m²) are doing it primarily for a better health.

(Business Wire India; 18th July, 2014); For three-year-old Sneha, life is a struggle in continuity. A patient of Thalassemia major, Sneha battles death every single day. Her parents, despite being advised to undergo medical tests to diagnose her condition when she was in her mother’s womb, chose to disregard this warning. Now, this unawareness and lack of understanding might cost them dear. Unfortunately, they lost their four-year-old son two years ago due to the same blood disorder.

(Business Wire India; 10th July, 2014); Celgene Corporation (NASDAQ:CELG) announced results of its phase III POSTURE study evaluating OTEZLA, the company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with active ankylosing spondylitis. The OTEZLA arms did not achieve statistically significant improvement versus the placebo arm for the primary endpoint, the percentage of patients who achieve an ASAS (Assessment of SpondyloArthritis international Society) 20 response at week 16. However, in a prespecified analysis, meaningful efficacy was observed at Week 24 in a large subset of patients with early-stage disease. Evaluation of the efficacy results is ongoing.

(Business Wire India; 9th July, 2014); HealthCare Global Enterprises Ltd, The Specialist in Cancer Care, organized a press conference on the topic cancer patients suffer due to non availability of drugs.

(Business Wire India; 20th June, 2014); Boehringer Ingelheim today announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation (AF). The RE-CIRCUIT™ study will investigate the safety and efficacy of uninterrupted anticoagulant treatment with Pradaxa® in patients with AF who undergo ablation. Results of the study are expected in 2016.

(Business Wire India; 19th June, 2014); Wincere Inc., a visionary full service contract research organization and life sciences  focused consulting company today organized a panel discussion in association with International CMEs Oncology on “Precision Medicine – Trends in Oncology”, promising to revolutionize cancer research.

(Business Wire India; 16th June, 2014); Acute myeloid leukaemia (AML) is a devastating form of blood cancer that mainly affects people over 60 years old. For older patients who receive chemotherapy, the median survival is less than a year. Even though AML is considered rare, it accounts for around 18,860 new cases and 10,000 deaths in the US each year and is the most frequent cause of leukaemia-related deaths.